TRPV1 and bone cancer: There are many chemokines, cytokines and other factors that are released in the bone cancer microenvironment including prostaglandins, bradykinin, NGF, lysophosphatidic acid, and parathyroid hormone-related peptide, which have been shown to (or could presumably) sensitize TRPV1 currents leading to increased nociceptor firing [85,209,211,212,213].